Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No history of genital warts, vulvar intraepithelial neoplasia (VIN), or vaginal intraepithelial neoplasia (VaIN)~* Not pregnant and agrees to use effective contraception through Month 7 of the study~* Additional criteria applied~Exclusion Criteria:~* Pregnant~* Concurrently enrolled in a clinical study involving collection of cervical specimens~* Previously received any HPV vaccine~* History of severe allergic reaction that required medical intervention~* Received any immune globulin or blood-derived products within 3 months prior to the first study injection~* History of splenectomy, known immune disorders, or receiving immunosuppressives~* Immunocompromised or diagnosed with human immunodeficiency virus (HIV) infection~* Known thrombocytopenia or any coagulation disorders that could contraindicate intramuscular injections~* History of recent or ongoing alcohol or drug abuse~* Prior treatment for genital warts, VIN, or VaIN~* History of cervical disease (ie, surgical treatment for cervical lesions)~* Hysterectomy

- Gender: FEMALE
- Minimum Age: 24 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- qHPV Vaccine in Base Study (Type: EXPERIMENTAL): Participants received blinded qHPV vaccination at Day 1, Month 2, and Month 6 of the Base Study
- Placebo in Base Study (Type: PLACEBO_COMPARATOR): Participants received blinded placebo at Day 1, Month 2, and Month 6 in the Base Study. They were eligible to receive open-label qHPV vaccine in Extension 1

Based on this trial design, predict the completion outcome and termination type (if applicable).